Oprelvekin biosimilar (Hangzhou Jiuyuan Gene Engineering)

重组人白介素-11（酵母）（杭州九源基因工程）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOprelvekin biosimilar (Hangzhou Jiuyuan Gene Engineering)
Drug Alias Nameoprelvekin follow-on biologic(Hangzhou Jiuyuan Gene Engineering)奥普瑞白介素-11 生物仿制药（杭州九源基因工程）奥普瑞白介素生物仿制药（杭州九源基因工程）Recombinant Human Interleukin-11(Hangzhou Jiuyuan Gene Engineering)oprelvekin follow-on biologic (Hangzhou Jiuyuan Gene Engineering) +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterleukin 11 receptor alpha stimulants
TargetsInterleukin 11 receptor alpha
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date2003/09/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC02
Related LinksN/A